VTRS

Viatris's stock price has experienced significant movement in the past six months, increasing by 30.49% over the last 6 months and 72.73% over the last 12 months, with a year-to-date return of 37.35%. Key events impacting the stock include Fitch Ratings revising the Outlook on Viatris Inc.'s Long-Term Issuer Default Rating (IDR) to Stable from Negative and affirming the IDR at 'BBB' on April 29, 2026, reflecting expectations of declining EBITDA leverage and sustained revenue growth. On May 7, 2026, Viatris announced its first-quarter 2026 financial results, reporting total revenues of $3.5 billion (8% reported growth) and reaffirming its 2026 financial guidance. On August 6, 2026, Viatris reported better-than-expected Q2 2026 earnings, with sales up 4.9% year-on-year to $3.76 billion and a non-GAAP profit of $0.69 per share. On October 9, 2026, Viatris announced its acquisition of Pacira BioSciences for $1.65 billion, a strategic move to boost its pain management portfolio with high-margin, patent-protected products.